Endometrial Cancer

Overview

Journal Nat Rev Dis Primers

Specialty General Medicine

Date 2021 Dec 10

PMID 34887451

Citations 185

Authors

Vicky Makker

Helen MacKay

Isabelle Ray-Coquard

Douglas A Levine

Shannon N Westin

Daisuke Aoki

Ana Oaknin

Affiliations

Soon will be listed here.

Abstract

Although endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy. This comprehensive review provides an update on the epidemiology, pathophysiology, diagnosis and molecular classification, recent advancements in disease management, as well as important patient quality-of-life considerations and emerging developments in the rapidly evolving therapeutic landscape of endometrial cancers.

Citing Articles

Anticancer potential of purified laccase enzyme from Trametes versicolor: specific cytotoxicity against thyroid and endometrial cancer cells.

Kale Bakir E, Deveci Ozkan A, Erman G, Isik S, Yuzugullu Karakus Y Mol Biol Rep. 2025; 52(1):312.

PMID: 40085415 DOI: 10.1007/s11033-025-10416-3.

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.

Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer.

Mamat Yusof M, Chew K, Kampan N, Hafizz A, Shafiee M PLoS One. 2025; 20(3):e0312765.

PMID: 40043041 PMC: 11882069. DOI: 10.1371/journal.pone.0312765.

Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes.

Anca-Stanciu M, Manu A, Olinca M, Coroleuca C, Comandasu D, Coroleuca C J Clin Med. 2025; 14(4).

PMID: 40004914 PMC: 11856752. DOI: 10.3390/jcm14041385.

Estrogen Promotes Endometrial Cancer Development by Modulating ZNF626, SLK, and RFWD3 Gene Expression and Inducing Immune Inflammatory Changes.

Fan J, Zhang M, Wu H, Ye Z, Wang L Biomedicines. 2025; 13(2).

PMID: 40002911 PMC: 11853163. DOI: 10.3390/biomedicines13020498.

References

Teng F, Tian W, Wang Y, Zhang Y, Guo F, Zhao J . Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016; 9:8. PMC: 4744391. DOI: 10.1186/s13045-015-0231-4. View

Watkins J, Yang E, Muto M, Feltmate C, Berkowitz R, Horowitz N . Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2016; 36(2):115-127. DOI: 10.1097/PGP.0000000000000312. View

Sorbe B, Nordstrom B, Maenpaa J, Kuhelj J, Kuhelj D, Okkan S . Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009; 19(5):873-8. DOI: 10.1111/IGC.0b013e3181a6c9df. View

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks C . Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clin Cancer Res. 2018; 25(8):2537-2548. DOI: 10.1158/1078-0432.CCR-18-3241. View

Setiawan V, Yang H, Pike M, McCann S, Yu H, Xiang Y . Type I and II endometrial cancers: have they different risk factors?. J Clin Oncol. 2013; 31(20):2607-18. PMC: 3699726. DOI: 10.1200/JCO.2012.48.2596. View

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

Ryan N, Glaire M, Blake D, Cabrera-Dandy M, Evans D, Crosbie E . The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019; 21(10):2167-2180. PMC: 8076013. DOI: 10.1038/s41436-019-0536-8. View

Kitchener H, Swart A, Qian Q, Amos C, Parmar M . Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2008; 373(9658):125-36. PMC: 2646126. DOI: 10.1016/S0140-6736(08)61766-3. View

Hecht J, Mutter G . Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006; 24(29):4783-91. DOI: 10.1200/JCO.2006.06.7173. View

10.

Abu-Rustum N, Chi D, Leitao M, Oke E, Hensley M, Alektiar K . What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?. Gynecol Oncol. 2008; 111(1):46-8. DOI: 10.1016/j.ygyno.2008.06.010. View

11.

Kurra V, Krajewski K, Jagannathan J, Giardino A, Berlin S, Ramaiya N . Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging. 2013; 13:113-22. PMC: 3613792. DOI: 10.1102/1470-7330.2013.0011. View

12.

Konstantinopoulos P, Luo W, Liu J, Gulhan D, Krasner C, Ishizuka J . Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019; 37(30):2786-2794. PMC: 9798913. DOI: 10.1200/JCO.19.01021. View

13.

Wortman B, Creutzberg C, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9):1067-1074. PMC: 6219495. DOI: 10.1038/s41416-018-0310-8. View

14.

Vermij L, Smit V, Nout R, Bosse T . Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2019; 76(1):52-63. PMC: 6972558. DOI: 10.1111/his.14015. View

15.

De Nola R, Menga A, Castegna A, Loizzi V, Ranieri G, Cicinelli E . The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication. Int J Mol Sci. 2019; 20(10). PMC: 6567055. DOI: 10.3390/ijms20102401. View

16.

Van den Heerik A, Horeweg N, Nout R, Lutgens L, van der Steen-Banasik E, Westerveld G . PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020; 30(12):2002-2007. PMC: 7788476. DOI: 10.1136/ijgc-2020-001929. View

17.

Talhouk A, McConechy M, Leung S, Yang W, Lum A, Senz J . Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5):802-813. DOI: 10.1002/cncr.30496. View

18.

Saed L, Varse F, Baradaran H, Moradi Y, Khateri S, Friberg E . The effect of diabetes on the risk of endometrial Cancer: an updated a systematic review and meta-analysis. BMC Cancer. 2019; 19(1):527. PMC: 6544993. DOI: 10.1186/s12885-019-5748-4. View

19.

Nagao S, Nishio S, Okada S, Otsuki T, Fujiwara K, Tanabe H . What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study. Cancer Chemother Pharmacol. 2015; 76(2):335-42. DOI: 10.1007/s00280-015-2793-9. View

20.

Janda M, Gebski V, Brand A, Hogg R, Jobling T, Land R . Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncol. 2010; 11(8):772-80. DOI: 10.1016/S1470-2045(10)70145-5. View